Monday, August 31, 2026

NIO Stock Was Up By 6.11% Today

ViaNews Editorial Team

December 15, 2020

NIO Stock Was Up By 6.11%  Today

The New York Stock Exchange ended the session with NIO jumping 6.11% to $43.49 on Tuesday, after two successive sessions in a row of losses. The New York Stock Exchange jumped 1.31% to $14,401.10, after two consecutive sessions in a row of losses, on what was an all-around positive trend exchanging session today.

NIO today's close was $43.49, 31.52% under its 52-week high of $57.20.

NIO's Sales

NIO's sales growth is 138% for the present quarter and 264.4% for the next. The company's growth estimates for the ongoing quarter and the next is 74.4% and 47.8%, respectively.

NIO's Stock Top and Bottom Yearly Value

NIO's stock is valued at $43.49 at 16:21 EST, way under its 52-week high of $57.20 and way above its 52-week low of $2.11.

NIO's Moving Average

NIO's value is above its 50-day moving average of $42.98 and way above its 200-day moving average of $21.95.

Previous days news about NIO

Tesla’s chinese rival nio joins race for cash with share sale. According to Bloomberg Quint on Fri Dec 11,

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com